Design Considerations for Pharmacokinetic Studies During Pregnancy
The Journal of Clinical Pharmacology · 2023-06 · 63 (S1)
DOI: 10.1002/jcph.2238 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 14.06.2023. Verfasst von Catherine S Stika und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Fetus, Research Personnel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Most of the interventions performed by obstetric providers involve the administration of drugs. Pregnant patients are pharmacologically and physiologically different from nonpregnant young adults. Therefore, dosages that are effective and safe for the general public may be inadequate or unsafe for the pregnant patient and her fetus. Establishing dosing regimens appropriate for pregnancy requires evidence generated from pharmacokinetic studies performed in pregnant people. However, performing these studies during pregnancy often requires special design considerations, evaluations of both maternal and fetal exposures, and recognition that pregnancy is a dynamic process that changes as gestational age advances. In this article, we address design challenges unique to pregnancy and discuss options for investigators, including timing of drug sampling during pregnancy, appropriate selection of control groups, pros and cons of dedicated and nested pharmacokinetic studies, single‐dose and multiple‐dose analyses, dose selection strategies, and the importance of integrating pharmacodynamic changes into these protocols. Examples of completed pharmacokinetic studies in pregnancy are provided for illustration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois, USA.
- Departments of Pharmacy and Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Catherine S Stika, Mary F Hebert
Förderung
- NIGMS NIH HHS
- NICHD NIH HHS
Zitieren
APA
Stika, C. S., & Hebert, M. F. (2023). Design Considerations for Pharmacokinetic Studies During Pregnancy. The Journal of Clinical Pharmacology, 63(S1). https://doi.org/10.1002/jcph.2238
Vancouver
Stika CS, Hebert MF. Design Considerations for Pharmacokinetic Studies During Pregnancy. The Journal of Clinical Pharmacology. 2023;63(S1). doi:10.1002/jcph.2238
BibTeX
@article{Stika2023,
author = {Stika, Catherine S and Hebert, Mary F},
title = {Design Considerations for Pharmacokinetic Studies During Pregnancy},
journal = {The Journal of Clinical Pharmacology},
year = {2023},
volume = {63},
number = {S1},
doi = {10.1002/jcph.2238}
}
EUVIMED